SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-21-001522
Filing Date
2021-03-04
Accepted
2021-03-04 07:32:12
Documents
14
Period of Report
2021-03-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_030421.htm   iXBRL 8-K 14434
2 PRESS RELEASE exh_991.htm EX-99.1 64840
  Complete submission text file 0001171843-21-001522.txt   294659

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3095
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25969
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 35566
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 24600
7 EXTRACTED XBRL INSTANCE DOCUMENT f8k_030421_htm.xml XML 3032
Mailing Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8 604-419-3200
Arbutus Biopharma Corp (Filer) CIK: 0001447028 (see all company filings)

IRS No.: 980597776 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34949 | Film No.: 21712585
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences